Vetoquinol SA (VETO.PA) fair value

ACCE thesis

Vetoquinol makes veterinary medicines, including anti-infectives, anti-inflammatories and anaesthetic products for companion animals and livestock, and sells them through its own subsidiaries in Europe and North America. The moat is mostly distribution and regulatory approval: a veterinary product needs its own marketing authorisation, and a 59.1% gross margin on a 15.1% operating margin suggests the portfolio is priced for specialist use rather than commoditised. Revenue growth has nearly stalled at 0.6%, so the investment case rests on margin recovery, pipeline launches and the cash that comes from them rather than on top-line expansion. At 14.4 times trailing earnings and 13.8 times forward, the stock is not priced for a growth story, which makes the margin trajectory the thing to test. The ROE of 10.7% is respectable but not exceptional for a company of this size, and the flat revenue line is the main reason a deeper look is needed before anyone assumes the moat is widening.